Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.

Journal article

Striant SR (marketed as Striant in the US) is a novel sustained-release mucoadhesive buccal testosterone tablet for the treatment of male hypogonadism. Striant SR restores serum testosterone concentrations to the physiological range within 4 h of application, and steady-state concentrations are achieved within 24 h of twice-daily dosing. In phase III clinical trials, 87-97% of patients using Striant SR achieved 24-h-averaged serum testosterone concentrations within the normal range. In a comparative study, Striant SR was more likely to restore testosterone concentrations to the physiological range than Andropatch. In a small study, Striant SR produced steady-state testosterone concentrations comparable with those achieved with a testosterone gel (50mg testosterone). Striant SR was well tolerated, with a low incidence of adverse events and a low discontinuation rate (3.5%) due to adverse events in phase III studies. Striant SR is an effective, well-tolerated, convenient and discreet treatment for male hypogonadism.

Authors: Korbonits, M; Kipnes, M; Grossman, AB

• Publication status: Published
• Journal: International journal of clinical practice
• Volume: 58
• Issue: 11
• Pages: 1073-1080
• Publication date: 2004-11-01
• DOI: 10.1111/j.1368-5031.2004.00383.x
• EISSN: 1742-1241
• ISSN: 1368-5031
• Language: English
• Keywords: Hypogonadism; Delayed-Action Preparations; Administration, Buccal; Tablets; Male; Treatment Outcome; Humans; Testosterone; Gels; Clinical Trials, Phase III as Topic